首页> 外文期刊>European journal of medical research. >Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study
【24h】

Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study

机译:骨髓间充质干细胞对小鼠模型高潜能肝细胞癌的影响:一项干预研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: There are two completely contradictory views regarding the impact of human bone-marrow-derived mesenchymal stem cells (hMSCs) on hepatocellular carcinomas (HCCs). The aim of this study was to investigate the effect of hMSC engraftment on HCC tissues in nude mouse models, and assess the effect on metastatic potential of HCC.Methods: hMSCs were engrafted into the nude mouse models of high metastatic HCC via the tail vein. The mice in the experimental group were engrafted with hMSCs (5 x 10s cells per mouse) via the tail vein 15 days after inoculation of tumor cells, twice a week, while the animals in the control group were injected with hMSC culture medium (0.2 ml_ per mouse) via the tail vein. The subcutaneous tumor size was measured using an electronic digital caliper once every 4 days after hMSC engraftment. After 2, 3,4, 5 and 6 weeks of tumor cell inoculation, the mice were killed and the tumors were collected in their entirety. The tumor weights and body weights of mice were measured, and the tumor inhibition rate was calculated. Quantitative real-time polymerase chain reaction (RT-PCR) was used to determine the expression of metastasis-related genes including osteopontin (OPN), bone sialoprotein (BSP) and integrin ct5 subunit (ct-V) in the mouse models of high-metastatic HCC, and the expression of apoptosis-related genes including B cell lymphoma/leukemia-2 (Bcl2), Bcl-2 associated X protein (Bax) and caspase 3 in tumor samples.Results: The tumor weight inhibition rate was 26.62% at 2 weeks, 52.00% at 3 weeks, 38.20% at 4 weeks, 31.98% at 5 weeks, and 30.23% at 6 weeks. Tumor tissue weight comparison results were significantly lower in the hMSC engraftment groups than in the control group at the second and third weeks. The expression of metastasis-related factors OPN, BSP and ct-V gene was downregulated with time. The expression of antiapoptotic gene Bcl2 exhibited an obvious declining tendency, while the expression of apoptotic genes Bax and caspase 3 showed an obvious rising tendency. The expression of ct-V and BSP significantly correlated positively with the expression of Bcl2, and negatively correlated with the expression of Bax and caspase 3. The tumor inhibition rate was not significantly correlated with the expression of antiapoptotic and apoptotic factors, and ct-V and BSP factors, though it exhibited a significantly negative correlation with the expression of OPN.Conclusions: The highest tumor inhibition rate was observed 3 weeks after hMSCs engraftment, and the tumor inhibition rate gradually reduced with the progression of time. The metastatic potential of tumor cells was downregulated after hMSC engraftment and hMSCs induce further tumor cells apoptosis. The decrease in the proliferation ability of tumor cells may induce a decline in metastatic potential in tumor cells.
机译:背景:关于人类骨髓间充质干细胞(hMSCs)对肝细胞癌(HCCs)的影响,存在两种完全矛盾的观点。本研究旨在探讨hMSCs移植对裸鼠肝癌组织的影响,并评估其对肝癌转移潜能的影响。方法:将hMSCs通过尾静脉移植入高转移性肝癌裸鼠模型。接种肿瘤细胞后15天,每周两次将实验组的小鼠经尾静脉移植hMSCs(每只小鼠5 x 10s细胞),对照组注射hMSC培养基(0.2 mL)。每只老鼠)通过尾静脉。 hMSC植入后每4天使用电子数字卡尺测量皮下肿瘤大小。接种肿瘤细胞2、3、4、5和6周后,处死小鼠并完整收​​集肿瘤。测量小鼠的肿瘤重量和体重,并计算肿瘤抑制率。实时定量聚合酶链反应(RT-PCR)用于确定与转移相关的基因的表达,包括骨桥蛋白(OPN),骨唾液蛋白(BSP)和整联蛋白ct5亚基(ct-V)。转移性HCC以及肿瘤样品中B细胞淋巴瘤/白血病2(Bcl2),Bcl-2相关X蛋白(Bax)和caspase 3等凋亡相关基因的表达。结果:肿瘤重量抑制率为26.62%。 2周,3周时52.00%,4周时38.20%,5周31.98%和6周30.23%。在第二周和第三周,hMSC植入组的肿瘤组织重量比较结果显着低于对照组。转移相关因子OPN,BSP和ct-V基因的表达随时间下调。抗凋亡基因Bcl2的表达呈明显下降趋势,而凋亡基因Bax和caspase 3的表达呈明显上升趋势。 ct-V和BSP的表达与Bcl2的表达显着正相关,与Bax和caspase 3的表达呈负相关。肿瘤抑制率与抗凋亡和凋亡因子以及ct-V的表达不显着相关。结论:hMSCs植入3周后,抑瘤率最高,且随时间的延长逐渐降低。 hMSC植入后,肿瘤细胞的转移潜能被下调,hMSCs进一步诱导肿瘤细胞凋亡。肿瘤细胞增殖能力的降低可引起肿瘤细胞转移潜能的降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号